Descemet's stripping without endothelial keratoplasty

Curr Opin Ophthalmol. 2019 Jul;30(4):275-285. doi: 10.1097/ICU.0000000000000579.

Abstract

Purpose of review: To summarize the recent literature regarding descemetorhexis stripping without endothelial keratoplasty (DWEK), increasingly referred to as Descemet's stripping only (DSO). To report the characteristic clinical, confocal and histologic findings associated with this procedure.

Recent findings: Reported clearance rates following DSO range from 63 to 100% in recent series, with variation between surgical techniques. Topical Rho-kinase inhibitor has been reported as successfully salvaging failing cases. Its use as an adjuvant to the surgery is gaining widespread adoption with the results of early series now arriving. Apart from a phenotype of central guttata with clear periphery, patient characteristics which determine success remain elusive. Surgical factors affecting success are increasingly well understood, with stromal injury felt to be a retardant to healing. Characteristic clinical signs have been observed and are described herein. Clinical, confocal and light microscopic images are obtained from patients in clinical trials of DSO with ripasudil.

Summary: DSO is gaining acceptance as a surgical option for a subset of patients with Fuchs' Dystrophy. The addition of Rho-associated kinase inhibitor appears to improve predictability but further results to this effect must be published and scrutinized.

Publication types

  • Review

MeSH terms

  • Descemet Membrane / surgery*
  • Descemet Stripping Endothelial Keratoplasty / methods*
  • Endothelium, Corneal / surgery
  • Fuchs' Endothelial Dystrophy / physiopathology
  • Fuchs' Endothelial Dystrophy / surgery*
  • Humans
  • Isoquinolines / therapeutic use
  • Sulfonamides / therapeutic use
  • Visual Acuity / physiology
  • rho-Associated Kinases / antagonists & inhibitors

Substances

  • Isoquinolines
  • K-115
  • Sulfonamides
  • rho-Associated Kinases